mTOR: An attractive therapeutic target for osteosarcoma?
mTOR: An attractive therapeutic target for osteosarcoma?
复制标题
mTOR：骨肉瘤有吸引力的治疗靶点？
DOI：
10.18632/oncotarget.9305
复制
发表时间：
2016-08-02
期刊：
影响因子：
--
通讯作者：
Zhihong L
中科院分区：
文献类型：
--
作者：
Ding L;Congwei L;Bei Q;Tao Y;Ruiguo W;Heze Y;Bo D;Zhihong L
骨肉瘤是一种常见的原发性恶性骨肿瘤，发病率和死亡率高，好发于儿童和青壮年。如何改善因化疗耐药而导致的预后不良的OS仍是一个挑战。近年来，越来越多的研究表明，哺乳动物雷帕霉素靶蛋白（mTOR）的激活与OS细胞的生长、增殖、转移有关。本文综述了mTOR通路在OS中的作用以及mTOR抑制剂在OS中的研究现状，并探讨了mTOR抑制剂与其他药物联合应用对OS的治疗方案。
Osteosarcoma (OS) is a common primary malignant bone tumor with high morbidity and mortality in children and young adults. How to improve poor prognosis of OS due to resistance to chemotherapy remains a challenge. Recently, growing findings show activation of mammalian target of rapamycin (mTOR), is associated with OS cell growth, proliferation, metastasis. Targeting mTOR may be a promising therapeutic approach for treating OS. This review summarizes the roles of mTOR pathway in OS and present research status of mTOR inhibitors in the context of OS. In addition, we have attempted to discuss how to design a better treatment project for OS by combining mTOR inhibitor with other drugs.